Surveillance of antimicrobial susceptibility trends is critical for monitoring the initial and continued in vitro effectiveness of any antibacterial agent in clinical development. Such studies are usually undertaken within three years of expected filing. The data are essential to the submission for corroborating a product’s in vitro activity observed during clinical trials. IHMA’s experience in designing and conducting successful surveillance is unparalleled and encompasses every region in the world and any clinically relevant pathogen for which a product’s regulatory submission is being prepared.